Moleculin Biotech
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 18
- Market Cap
- -
- Website
- http://www.moleculin.com
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Conditions
- Acute Myeloid Leukaemia (AML)
- Interventions
- Drug: Placebo in combination with Cytarabine InjectionDrug: Liposomal Annamycin Injection in combination with Cytarabine InjectionDrug: Liposomal Annamycin for Injection in combination with Cytarabine Injection.
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 334
- Registration Number
- NCT06788756
- Locations
- 🇺🇦
ARENSIA Exploratory Medicine, Kyiv, Ukraine
Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05319587
- Locations
- 🇮🇹
Istituto Scientifico Romagolo per lo studio dei umori "Dino Amadori" (IRST) - IRCCS, Meldola, FC, Italy
🇵🇱Uniwersytecki Szpital Kliniczny Klinika Hematologii Nowotworow, Wrocław, Dolnośląskie województwo, Poland
🇮🇹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05195723
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
- Conditions
- Sarcoma,Soft TissuePulmonary Metastasis
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04887298
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04702503
- Locations
- 🇵🇱
Medical University of Gdansk, Gdansk, Poland
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03388749
- Locations
- 🇵🇱
Samodzielny Szpital Kliniczny nr 1, Wrocław, Poland
🇵🇱Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland
🇵🇱Samodzielny Publiczny Szpital Kliniczny nr 1 im. Prof. Tadeusza Sokołowskiego w Szczecinie, Klinika Hematologii z Oddziałem Transplantacji Szpiku, Szczecin, Poland
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03315039
- Locations
- 🇺🇸
UC San Diego Health, La Jolla, California, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Southwest Cancer Center, Lubbock, Texas, United States